Show simple item record

dc.contributor.authorBarnes, Karen I.en_US
dc.contributor.authorLindegardh, Niklasen_US
dc.contributor.authorOgundahunsi, Olumideen_US
dc.contributor.authorOlliaro, Pieroen_US
dc.contributor.authorPlowe, Christopher V.en_US
dc.contributor.authorRandrianarievelojosia, Milijaonaen_US
dc.contributor.authorGbotosho, Grace O.en_US
dc.contributor.authorWatkins, William M.en_US
dc.contributor.authorSibley, Carol Hopkinsen_US
dc.contributor.authorWhite, Nicholas J.en_US
dc.date.accessioned2010-05-06T20:06:11Z
dc.date.available2010-05-06T20:06:11Z
dc.date.issued2007en_US
dc.identifier.citationBarnes K, Lindegardh N, Ogundahunsi O, et al. World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology. Malaria Journal. 2007;6(1):122.en_US
dc.identifier.other10.1186/1475-2875-6-122en_US
dc.identifier.urihttp://www.malariajournal.com/content/6/1/122en_US
dc.identifier.urihttp://hdl.handle.net/1773/15845
dc.description.abstractA World Antimalarial Resistance Network (WARN) database has the potential to improve the treatment of malaria, through informing current drug selection and use and providing a prompt warning of when treatment policies need changing. This manuscript outlines the contribution and structure of the clinical pharmacology component of this database. The determinants of treatment response are multi-factorial, but clearly providing adequate blood concentrations is pivotal to curing malaria. The ability of available antimalarial pharmacokinetic data to inform optimal dosing is constrained by the small number of patients studied, with even fewer (if any) studies conducted in the most vulnerable populations. There are even less data relating blood concentration data to the therapeutic response (pharmacodynamics). By pooling all available pharmacokinetic data, while paying careful attention to the analytical methodologies used, the limitations of small (and thus underpowered) individual studies may be overcome and factors that contribute to inter-individual variability in pharmacokinetic parameters defined. Key variables for pharmacokinetic studies are defined in terms of patient (or study subject) characteristics, the formulation and route of administration of the antimalarial studied, the sampling and assay methodology, and the approach taken to data analysis. Better defining these information needs and criteria of acceptability of pharmacokinetic-pharmacodynamic (PK-PD) studies should contribute to improving the quantity, relevance and quality of these studies. A better understanding of the pharmacokinetic properties of antimalarials and a more clear definition of what constitutes "therapeutic drug levels" would allow more precise use of the term "antimalarial resistance", as it would indicate when treatment failure is not caused by intrinsic parasite resistance but is instead the result of inadequate drug levels. The clinical pharmacology component of the WARN database can play a pivotal role in monitoring accurately for true antimalarial drug resistance and promptly correcting sub-optimal dosage regimens to prevent these contributing to the emergence and spread of antimalarial resistance.en_US
dc.description.sponsorshipBill and Melinda Gates Foundation.en_US
dc.language.isoen_USen_US
dc.titleWorld Antimalarial Resistance Network (WARN) IV: Clinical pharmacologyen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record